Bristol-Myers Squibb (NY:BMY)

Shares of these companies are trading at sizable earnings discounts.

Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside ↗

February 21, 2024

Via The Motley Fool

Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes ↗

February 20, 2024

Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as...

Via Benzinga

Topics Cannabis

U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...

February 20, 2024

Patience will be rewarded with these stocks.

Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb ↗

February 09, 2024

Via Benzinga

Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment ↗

February 05, 2024

Via Benzinga

Is It Too Late to Buy These 2 Brilliant Passive Income Stocks? ↗

February 17, 2024

Via The Motley Fool

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes

February 14, 2024

Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC

February 14, 2024

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

February 14, 2024

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

From FN Media Group LLC

Via GlobeNewswire

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields ↗

February 14, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

A Look At Pharma ETFs After Q4 Earnings ↗

February 12, 2024

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.

Via Talk Markets

Topics ETFs

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)

February 12, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

7 Dividend Stocks to Buy at a 52-Week Low ↗

February 12, 2024

Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround.

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

February 12, 2024

Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare ↗

February 09, 2024

Via Benzinga

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Cytokinetics is looking to take on Bristol Myers Squibb in treating a heart disease.

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month ↗

February 08, 2024

Via Investor's Business Daily

3 Blue-Chip Stocks to Buy at a 52-Week Low in February ↗

February 07, 2024

Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

Pancreatic Cancer Treatments Poised for Major Advances in 2024

February 07, 2024

Via FinancialNewsMedia

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

February 07, 2024

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗

February 06, 2024

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.

Via Benzinga

Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 06, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)

February 05, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC

February 05, 2024

Each of these seven undervalued stocks has fallen by 25% or more from its 52-week high, but may have a path back to prior prices.

Undervalued Gems: 7 Stocks Set for a Major Rebound ↗

February 05, 2024

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

February 05, 2024